AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01840033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnelled nutritional central catheter
Description: After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
Study NCT00818493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: IR Capsules, ascending flexible dose, every 4 to 6 hours
Study NCT00818493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
Study NCT00818493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet (oxycodone and acetaminophen)
Description: One or two 5mg/325 mg tablets every 4 to 6 hours
Study NCT04402307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chin Tuck Against Resistance
Description: Training in 6 weeks 3 times a day.
Study NCT02878876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk with sequence A1-A2
Description: Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
Study NCT02878876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk with sequence A2-A1
Description: Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
Study NCT03507127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
Study NCT03507127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
Study NCT03715530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
Study NCT04720469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Description: Ablation of untreated thalamus using focused ultrasound to abate tremor.
Study NCT01082614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigileo
Description: Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
Study NCT01750125 — intervention group
Intervention type: DEVICE
Intervention: measure ascending aortic blood flow with pulse wave Doppler
Study NCT01060787 — intervention group
Intervention type: PROCEDURE
Intervention: Fluocinolone Acetonide 0.59 mg
Description: At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
Study NCT01060787 — intervention group
Intervention type: PROCEDURE
Intervention: Fluocinolone Acetonide 2.1 mg
Description: At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
Study NCT03122938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin-supplemented formula
Description: Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
Study NCT03122938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: formula without lactoferrin supplementation
Description: Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
Study NCT02761642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
Study NCT00636181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto AFlex
Description: Positive pressure therapy treatment
Study NCT04430218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSens
Description: The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
Study NCT03298815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Fluid Eye Drops (AFED)
Description: One drop (0.25 mL) in one eye twice daily for up to 3 months
Study NCT03298815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: One drop (0.25 mL) in the other eye twice daily for up to 3 months
Study NCT02805010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: On Day 1, subjects will receive a single SC dose of abatacept 125mg
Study NCT02805010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 1, subjects will receive a single SC dose of placebo
Study NCT01645345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alma Lasers Accent RF Pixel handpiece
Description: Treatment with fractionated RF Pixel device
Study NCT00211510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paradigm 722 sensor augmented pump
Description: Subjects use the Paradigm 722 sensor augmented pump
Study NCT00211510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paradigm 715 insulin pump
Description: Subjects use the Paradigm 715 insulin pump
Study NCT03794271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupilometer guided anesthesia
Description: At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml.
Study NCT03794271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPI guided anesthesia
Description: During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
Study NCT04753645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwashing stations at the public places and no soap
Description: BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
Study NCT04753645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No activities of the HBCC project and also no soap (Pure Control)
Description: In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
Study NCT04753645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap distributed but no activities of the HBCC project
Description: In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
Study NCT00636181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP
Description: Positive pressure therapy treatment
Study NCT04753645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBCC project and Soap
Description: These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
Study NCT00636181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Positive pressure therapy treatment
Study NCT03034707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: biotin
Study NCT03768427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Ator 10 mg
Description: FDC of EZ10 mg/Ator 10mg
Study NCT03768427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Ator 20 mg
Description: FDC of EZ10 mg/Ator 20mg
Study NCT03768427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Study NCT03768427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for FDC EZ/Ator
Description: A single placebo tablet administered orally QD for 84 days
Study NCT03768427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for atorvastatin
Description: Two placebo tablets matching atorvastatin administered orally QD for 84 days
Study NCT01440361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study NCT01440361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study NCT00499668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125 mg orally for 7 days
Study NCT00499668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron hydrochloride
Description: 24 mg orally for 7 days
Study NCT00411424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK8007
Description: IV
Study NCT00411424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT01487200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 10 mg
Description: single 3 mL IA injection
Study NCT02774434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JM-105
Description: Measurement of TcB via the JM-105 device
Study NCT01846936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DLT with conventional technique
Description: The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
Study NCT01846936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BB with conventional technique
Description: The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation.
Study NCT01846936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disconnection technique
Description: Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
Study NCT03608475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limited Ultrasound Imaging
Description: Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
Study NCT03608475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ultrasound Imaging
Description: Ultrasound imaging will be performed at all clinic visits
Study NCT04484935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Study NCT02745873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
Study NCT02793583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Study NCT02793583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Study NCT02793583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT01951664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Study Measures
Description: Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
Study NCT01951664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Study Measures
Description: Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
Study NCT01951664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Evaluation
Description: The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
Study NCT01951664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program
Description: The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
Study NCT01951664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Practice Plan
Description: To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
Study NCT01951664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Assessments
Description: Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
Study NCT01951664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Assessments
Description: Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
Study NCT04021290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/3TC FDC
Description: DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
Study NCT04021290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
Study NCT03487094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Multi-centered, prospective, randomized clinical trial
Study NCT05361850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Removal of the endotracheal tube
Study NCT02593448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia with propofol use
Description: Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.
Study NCT01664754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT01664754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01664754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02593448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anaesthesia with sevoflurane use
Description: Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.
Study NCT01664754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01664754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01664754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01664754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03289533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Study NCT03289533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Study NCT01030822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, administered as a single dose
Study NCT01030822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 3 doses